A drug commonly used drug to control high blood pressure may be also effective in preventing the onset of Type 1 diabetes in up to 60 per cent of those at risk, researchers say.
The drug, methyldopa, has been used for over 50 years to treat high blood pressure in pregnant women and children and is also on the World Health Organization's list of essential drugs.
Methyldopa was found to block a molecule called DQ8 -- found in some 60 per cent at the risk of getting Type 1 diabetes -- which significantly increases the chance of getting the disease.
Blocking specifically the DQ8 molecule could also block the onset of the disease, the study found.
"This is the first personalised treatment for Type 1 diabetes prevention," said Aaron Michels, Associate Professor of medicine at University of Colorado - Anschutz.
"With this drug, we can potentially prevent up to 60 per cent of Type 1 diabetes in those at the risk for the disease. This is very significant development," Michels added.
For the study, published in the Journal of Clinical Investigation, the team used a supercomputer, on the lab bench, in mice and in humans.
They found that methyldopa not only blocked DQ8, but it did not also harm the immune function of other cells like many immunosuppressant drugs do.
"We can now predict with almost 100 per cent accuracy who is likely to get Type 1 diabetes. The goal, with this drug, is to delay or prevent the onset of the disease among those at risk," Michels said.
The drug is taken orally, three times a day.
Besides, diabetes, the same approach of blocking specific molecules can be used in other autoimmune diseases such as rheumatoid arthritis, coeliac disease, multiple sclerosis, systemic lupus erythematosus and others, the researchers noted.
--IANS
rt/nks/vm
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
